Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket

Impact · against what's priced in

Inovio Pharmaceuticals is transitioning from a clinical-stage R&D entity to a commercial-stage company following FDA accelerated approval of Voceryq. This regulatory milestone provides a fundamental catalyst for revenue generation that was not previously reflected in the company's valuation.

INO+0.90

No priced-in read yet